Skip to content

Firm Record

Aqualex Co., Ltd.

10 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2024-06-18 ~ 2024-10-08

Areas cited

Equipment and facilityLaboratory and QC controlsStability and storageQuality unit oversightProcess validation

Published inspection documents

Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63). Your firm uses (b)(4) water as a component to manufacture your OTC drug product. You failed to adequately design your (b)(4) water system to ensure that it was suitable for producing water used in the formulation of your drug product. For example, your (b)(4) water system has points of stagnant water (e.g., a dead-leg), including one located at a point-of-use in the production area. Stagnant water can foster the development of biofilms. In your response, you state that you plan to implement a (b)(4) of the water system before production. Your response is inadequate. It did not demonstrate that your water system is of adequate design, control, maintenance, and monitoring, to consistently produce water suitable for its intended use as a component in your drug product. Your response also did not assess the impact of your inadequate water system design on the quality of the drug product you manufacture. The (b)(4) Water System must be adequately designed and properly maintained to minimize and/or eliminate the potential for contamination. (b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. In response to this letter, provide: • A comprehensive remediation plan for the design, control, and maintenance of the water system. o Validation report for the water system obtained after all identified design issues have been fully corrected and any maintenance repairs have been completed (such as the modifications required to remove all dead-legs). Include the system validation protocol, the complete test results, and the final validation report. • A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm. • The current action/alert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm. • A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits. 2024-06-18 US FDA 5 findingsEquipment and facility · Stability and storage and 3 more View the regulator's official source

21 CFR sections cited in FDA inspections

Citations from 1 FDA inspection (2023-10-20) of facilities listed under this company name in FDA's inspection citation data.

As written by FDAInspectionLatest inspection
21 CFR 211.160(a)Following/documenting laboratory controls12023-10-20
21 CFR 211.160(b)Scientifically sound laboratory controls12023-10-20
21 CFR 211.166(a)Lack of written stability program12023-10-20
21 CFR 211.22(d)Procedures not in writing, fully followed12023-10-20
21 CFR 211.48(a)Plumbing System Defects12023-10-20
21 CFR 211.67(c)Cleaning/maintenance records not kept12023-10-20

1 site: Aqualex Co., Ltd. (Seongnam, Korea (the Republic of)) · 1 inspection

Source: FDA Data Dashboard - Inspections Citations, as of 2026-11-08. Only inspections with at least one citation are included, and a section cited more than once in one inspection counts once. Only facilities whose name and legal form match this page's documents, and that are listed in a single country, are included.

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Aqualex Co., Ltd. — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.